Ratings NovoCure Limited

Equities

NVCR

JE00BYSS4X48

Real-time Estimate Cboe BZX Other stock markets 01:55:26 2023-11-29 pm EST			5-day change	1st Jan Change
12.30 ^USD	+0.82%		+3.52%	-83.18%

Nov. 28	Sector Update: Health Care Stocks Ease Tuesday Afternoon	MT
Nov. 28	Sector Update: Health Care	MT

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.
The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Over the past twelve months, analysts' opinions have been strongly revised upwards.

Weaknesses

According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company has insufficient levels of profitability.
The company is in debt and has limited leeway for investment
For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
For the past year, analysts have significantly revised downwards their profit estimates.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector : Medical Equipment, Supplies & Distribution

	1st Jan change	Capi. (M$)	ESG Refinitiv
NOVOCURE LIMITED	-83.18%	1 304 M $	C-
PENUMBRA, INC.	+1.53%	8 668 M $	C+
SHOCKWAVE MEDICAL, INC.	-18.12%	6 161 M $	B-
GETINGE AB	+4.44%	5 864 M $	B
ASAHI INTECC CO., LTD.	+30.57%	5 192 M $	B-
MASIMO CORPORATION	-36.65%	4 908 M $	C-
JIANGSU YUYUE MEDICAL EQUIPMENT & SUPPLY CO., LTD.	+5.96%	4 708 M $	D+
APT MEDICAL INC.	+18.63%	3 386 M $	-
INARI MEDICAL, INC.	-5.04%	3 355 M $	C
SHANDONG WEIGAO ORTHOPAEDIC DEVICE CO., LTD	-18.70%	2 407 M $	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes